Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03674567
Title Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors FLX Bio, Inc.
Indications

nasopharynx carcinoma

breast cancer

ovarian cancer

cervical cancer

triple-receptor negative breast cancer

stomach cancer

lung non-small cell carcinoma

esophageal carcinoma

lymphoma

head and neck squamous cell carcinoma

transitional cell carcinoma

colorectal adenocarcinoma

Therapies

FLX475 + Pembrolizumab

FLX475

Age Groups: adult | senior
Covered Countries USA | AUS


No variant requirements are available.